ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | ₹182 Cr revenue; YoY comparison invalid due to Numed acquisition consolidation. |
|---|---|
| Margins | Gross margin improved to 41.8%; EBITDA impacted by elevated air-freight costs. |
| Order book | 7.5-year exclusive OTC supply agreement with Ebos/TerryWhite worth ₹1300 Cr. |
| Demand visibility | Strong Australian order flow; West Asia disruption causing temporary shipping delays. |
| Management confidence | Confident but pivoting strategy due to local regulatory constraints on manufacturing. |
Growth
Consolidated revenue hit ₹182 Cr. Growth is non-comparable YoY due to Numed pharmaceutical's first-time full-quarter consolidation.
Outlook
Revenue guidance for FY27 held at ₹750 Cr with 17% EBITDA margin target.
Risks
Regulatory changes in Hyderabad halted planned unit upgrades; sudden 120-day price revision lags squeeze margins.
Earnings Call Transcript filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹507.05
- Market cap
- ₹2,240 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 89.9×Sector 43.8×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Earnings Call Transcript: Key Takeaways
Sai Parenterals is transitioning from a standalone unit to a consolidated manufacturing and R&D powerhouse through strategic acquisitions. While revenue grew 9% sequentially, high depreciation from new assets is currently masking operating profitability gains.
Sai Parenterals Other Announcement
Sai Parenterals filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters and promoter group hold 51.16 per cent.
Sai Parenterals Investor Presentation: Key Takeaways
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Sai Parenterals Results Update
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
Sai Parenterals Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 66.7% YoY
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +66.7% YoY